Research Abstract


Targeting JNK for therapeutic depletion of stem-like glioblastoma cells

2012年7月19日 Scientific Reports 2 : 516 doi: 10.1038/srep00516


松田 憲一朗1,2*, 佐藤 篤1,2*, 岡田 雅司1, 渋谷 慶太1, 清野 静香1, 鈴木 香1,3, 渡辺 江梨子1, 成田 善孝3, 渋井 壯一郎3, 嘉山 孝正2 & 北中 千史1,4,5

  1. 山形大学医学部 腫瘍分子医科学講座
  2. 山形大学医学部 脳神経外科学講座
  3. 国立がん研究センター中央病院 脳脊髄腫瘍科
  4. 山形大学 先端分子疫学研究所 悪性腫瘍研究センター
  5. グローバル COE プログラム
    *本研究は、松田 憲一朗、佐藤 篤の2研究者が同等に貢献した成果として論文発表しています。
Control of the stem-like tumour cell population is considered key to realizing the long-term survival of patients with glioblastoma, one of the most devastating human malignancies. To date, possible therapeutic targets and targeting methods have been described, but none has yet proven to target stem-like glioblastoma cells in the brain to the extent necessary to provide a survival benefit. Here we show that targeting JNK in vivo, the activity of which is required for the maintenance of stem-like glioblastoma cells, via transient, systemic administration of a small-molecule JNK inhibitor depletes the self-renewing and tumour-initiating populations within established tumours, inhibits tumour formation by stem-like glioblastoma cells in the brain, and provide substantial survival benefit without evidence of adverse events. Our findings not only implicate JNK in the maintenance of stem-like glioblastoma cells but also demonstrate that JNK is a viable, clinically relevant therapeutic target in the control of stem-like glioblastoma cells.